Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

For the state, the cost of funding obesity medications was too high. For the patients, the cost of losing access is higher.

With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

CELLEV8 Launches First Post-GLP-1 Gummy Supplement: 'SlimCell™' with Clinically Proven Ingredients to Compliment GLP-1 ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

A slowdown of the digestive tract (gastroparesis) can be a serious side effect, though. Researchers who analyzed the health records of 16 million people revealed that pancreatitis and bowel ...

For the uninitiated, both Zepbound (tirzepatide) and Wegovy (semaglutide) are weight loss drugs. They target hormones that ...